Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $629,182 | $572,952 | $561,347 | $548,970 |
| % Growth | 9.8% | 2.1% | 2.3% | – |
| Cost of Goods Sold | $324,203 | $304,629 | $268,225 | $252,314 |
| Gross Profit | $304,979 | $268,323 | $293,122 | $296,656 |
| % Margin | 48.5% | 46.8% | 52.2% | 54% |
| R&D Expenses | $64,536 | $52,243 | $54,540 | $60,152 |
| G&A Expenses | $0 | $85,086 | $57,057 | $52,813 |
| SG&A Expenses | $218,935 | $198,366 | $113,676 | $91,355 |
| Sales & Mktg Exp. | $0 | $113,280 | $56,620 | $38,542 |
| Other Operating Expenses | $0 | $2,462 | $0 | $0 |
| Operating Expenses | $283,471 | $250,609 | $168,216 | $151,507 |
| Operating Income | $21,508 | $17,714 | $184,366 | $704,438 |
| % Margin | 3.4% | 3.1% | 32.8% | 128.3% |
| Other Income/Exp. Net | $75,360 | $20,499 | -$47,060 | -$536,222 |
| Pre-Tax Income | $82,668 | $38,213 | $77,859 | -$391,073 |
| Tax Expense | $28,801 | $12,768 | $19,592 | $9,667 |
| Net Income | $53,867 | $25,445 | $58,266 | -$400,740 |
| % Margin | 8.6% | 4.4% | 10.4% | -73% |
| EPS | 1.43 | 0.68 | 1.55 | -10.49 |
| % Growth | 110.3% | -56.1% | 114.8% | – |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 |
| Weighted Avg Shares Out | 37,585 | 37,585 | 37,641 | 38,210 |
| Weighted Avg Shares Out Dil | 37,585 | 37,585 | 37,641 | 38,210 |
| Supplemental Information | – | – | – | – |
| Interest Income | $56,192 | $22,103 | $8,187 | $20,174 |
| Interest Expense | $0 | $1,253 | $1,653 | $1,363 |
| Depreciation & Amortization | $31,094 | $34,940 | $25,915 | $23,680 |
| EBITDA | $38,402 | $55,467 | $164,887 | -$413,775 |
| % Margin | 6.1% | 9.7% | 29.4% | -75.4% |